ATLAS: Adjuvant Tamoxifen Longer Against Shorter
Abstract
World-wide, more than 1 million women with early breast cancer take adjuvant tamoxifen. But, there is substantial uncertainty about the optimal duration of treatment, and in particular!, as to whether tamoxifen should be stopped after 5 years, or continued for longer-this has not been addressed adequately in the other small trials of this question. ATLAS is an international trial designed to assess this reliably. If the study demonstrates that longer treatment confers additional benefit, several thousands of deaths could be avoided each year if women are treated accordingly. With funding from the US Army BCRP, a world-wide - collaboration has been established. By early 1999, ATLAS will be the largest ever trial of tamoxifen duration. 32 countries are participating, 330 centres have ethics approval, 246 centres are randomizing. By 30111/1998, 3500 women had entered the study. Accrual should increase as more centres obtain ethics - approval and the 10-20,000 accrual target should be reached early in the millenium. 3 follow-up cycles have been undertaken demonstrating good treatment compliance in both study arms, and reliable and complete acquisition of follow-up data. Additional funding is required to maintain the collaboration to achieve the accrual target and long-term follow-up.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1998
- Accession Number
- ADA360842
Entities
People
- Richard Peto
Organizations
- University of Oxford